Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants
- Stolk, Leo M.
- de Vries, Frank
- Ebbelaar, Chiel
- de Boer, Anthonius
- Schalekamp, Tom
- Souverein, Patrick
- ten Cate-Hoek, Arina
- Burden, Andrea M.
DOIAbstract
AimDirect-acting oral anticoagulants (DOACs) have become available for the prevention of stroke in patients with atrial fibrillation (AF). Conflicting results have been published on the risk of acute myocardial infarction (AMI) with the use of DOACs in comparison with vitamin K antagonists (VKAs). The objective of the present study was to evaluate the risk of AMI in patients with AF who are exposed to either VKAs, DOACs or low-dose (<325mg) aspirin. MethodsWe conducted a population-based cohort study using data from the Clinical Practice Research Datalink (2008-2014). The study population (n=30146) consisted of all patients 18years with a diagnosis of AF who were new users of VKAs, DOACs (rivaroxaban and dabigatran) or aspirin. Cox proporti...
Add to ORKG